Analyst Rating Network 10/30/13
10/29/13 BTIG Target Facebook Inc. ( FB ) $68 View
10/28/2013 Credit Suisse Target Facebook Inc. (FB ) $ 61.00 View
10/24/2013 JMP Securities Set Price Target Facebook Inc. (FB) Market Outperform $65.00 View
10/22/2013 Needham & Company Reiterated Rating Facebook Inc. (FB) Buy $65.00 View
10/17/2013 Goldman Sachs Group Inc. Reiterated Rating Facebook Inc. (FB) Buy $58.00 View
10/15/2013 Evercore Partners Reiterated Rating Facebook Inc. (FB) Overweight $60.00 View10//2013Deutsche Bank Reiterated Rating Facebook Inc. (FB) Buy $62.00 View
10/7/2013 Topeka Capital Markets Boost Price Target Facebook Inc. (FB) Buy $60.00
Seeking Alpha Market Currents 9/24/13
Cantor raises price target on Celldex
Cantor Fitzgerald follows Leerink in hiking the price target on Celldex Therapeutics (CLDX) after the stock's recent move higher.
Once the shares rose above Cantor's previous target ($24), analyst Mara Goldstein knew just what to do: "Shares have experienced strength of late [and] we like CLDX's pipeline and the opportunity for continued valuation expansion based on catalyst events. Using a risk-adjusted revenue calculation of each [pipeline] candidate, plus the value of technology, early-stage assets, and cash, we see upside to $39."
The new target represents a 19% upside from Monday's close.
Facebook Profit Seen Removing Bar to S&P 500 Membership
By Inyoung Hwang Updated 11/23/13
Facebook Inc. (FB)’s fourth straight quarter of positive net income settles one of the final conditions for the 29th-biggest U.S. stock to join the benchmark Standard & Poor’s 500 Index 17 months after its trading debut.
The world’s largest social-networking service reported third-quarter profit of $425 million on Oct. 30 as advertisers boosted spending on promotions targeting mobile-device users. Shares in the Menlo Park, California-based company fell after its May 2012 initial public offering, only climbing back above the $38 offer price in July this year.
Enlarge image Facebook Logo
Facebook would join Google Inc., EBay Inc. and Yahoo! Inc. in the Internet software and services sub-sector, which makes up about 2.5 percent of the S&P 500, according to data provided by Howard Silverblatt of S&P Dow Jones Indices. Photographer: Daniel Acker/Bloomberg
Gaining entry to benchmark gauges provides companies with a guaranteed shareholder base from funds that follow the indexes. More than $5.1 trillion tracks the S&P 500, according to the index provider’s website.With a market value of $122 billion, Facebook is the largest U.S. company not in the index,Bloomberg data show. It could be added as early as this month, according to Stephen Casciano of Credit Suisse Group A
Wall Street " Tesla and Model S Owner Agree: Fire Was a Fluke "
Tesla and Model S Owner Agree: Fire Was a Fluke
Eric Schaal | More Articles
October 05, 2013
Page 1 of 2
Tesla model-s-signature-red-motionCall it the fire seen ’round the world. When a man driving a Tesla (NASDAQ:TSLA) Model S rammed into a large, angular metal object at highway speed, the electric vehicle’s battery pack burst into flames. Soon enough, the fire engulfed the front of the car. Yet the extraordinary circumstances of the event fazed neither car owner nor Tesla CEO Elon Musk. Days after the crash, both were calling the fire a fluke.
Musk described the event in detail in a blog post on Tesla’s website. The architect of the Model S wrote, “the geometry of the object caused a powerful lever action…impaling the Model S with a peak force on the order of 25 tons.” He added that only such a powerful force could puncture the armor plate underneath Tesla’s flagship vehicle. Since the fire was contained and the safety of the driver assured, Musk felt the test was passed.
Rob Carlson, the owner of the Model S in question, agreed wholeheartedly in an email reprinted on the Tesla site. Carlson described the occurrence as a freak event, a kind of “celestial bullet” engineers couldn’t have foreseen entering the picture. It turns out Carlson is also a Tesla investor and couldn’t wait to get back into a Model S (So, Tesla offered him a loaner). Carlson remarked the “Internet images really exaggerate” the fire, saying it was “a controlled burn.” Wall Street’s reaction was also exaggerated.
Page 1 of 2
earnings will rock.
Business Insider 10/30/13
Forrester Is Failing Marketers With BS Data About Facebook
Business InsiderBy Rob Leathern, Optimal | Business Insider
Just in time for Facebook earnings, Forrester is actively trying to get journalists to cite a ‘damning’ report about how Facebook is failing marketers. It’s a hatchet job with supporting ‘evidence’ that can only be described as bulls---. ( Read Rest of Story , It's Great )
Bought couple hundred shares, if this is next big internet stock, I will make alot of money, if not I lose a couple hundred..worth it.
All across the China-related media today is a story from South China Morning Post that the new Shanghai Free Trade Zone will allow users to access banned western social media platforms Facebook (FB) and Twitter, and allow foreign telecoms to operate there:
Beijing has made the landmark decision to lift a ban on internet access within the Shanghai Free-trade Zone to foreign websites considered politically sensitive by the Chinese government, including Facebook, Twitter
and JAZZ is $115 a share.
$60 by Wed. Here
By Shuli Ren
All across the China-related media today is a story from South China Morning Post that the new ShanghaiFree Trade Zone will allow users to access banned western social media platforms Facebook (FB) and Twitter, and allow foreign telecoms to operate there:
google to verify
Globe NewsAs previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
Celldex Reports First Quarter 2013 Financial Results CLDX Website,
"This year will be significant for Celldex as we continue to advance multiple clinical programs, including registration studies in both brain and breast cancer," said Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics. "We are well on track to initiate the accelerated approval study of CDX-011 in triple negative breast cancers that over-express GPNMB later this year and remain pleased with the pace of enrollment in both our Phase 3 study in frontline glioblastoma and our Phase 2 study in refractory glioblastoma. In addition, by year-end we expect data from three clinical studies—our Phase 2 study of rindopepimut in refractory glioblastoma, our pilot study of CDX-1135 in dense deposit disease and our
ongoing Phase 1 study of CDX-1127 in both solid tumors and hematologic malignancies. Importantly, these programs and others in our pipeline are well-financed given the successful completion of our $114.1 million capital raise in the first quarter."